Close Menu

NEW YORK – C2N Diagnostics said on Tuesday that its PrecivityAD blood test for Alzheimer's has received the CE Mark from the EU as well as approval from the state of California to test patients out of its CLIA facility.

With the CE Mark, C2N can offer the test in Europe as an in vitro diagnostic to aid in the evaluation of patients with mild cognitive impairment or very mild dementia who are undergoing assessment for Alzheimer's disease.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.